Dawn wakefulness drug could help pre-dawn workers stay alert

A NEJM Evidence trial found solriamfetol (Sunosi) improves wakefulness in early-morning workers with shift-work disorder, extending awake time by about 12.5 minutes on a full eight-hour shift versus placebo, with only modest side effects. This provides the first randomized evidence supporting a wakefulness drug for pre-dawn workers, and a follow-up trial in overnight workers is planned as a path toward formal labeling for shift-work disorder.